Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Overview of attention for article published in Frontiers in oncology, October 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 17 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 14,461 followers.

INPLASY202130104 - Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis https://t.co/FslTRmhq2K

02 Nov 2021

Reply Repost Favourite

RT @FrontOncology: New research: Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal…

15 Oct 2021

Reply Repost Favourite

RT @FrontOncology: New research: Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal…

14 Oct 2021

Reply Repost Favourite

New research: Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis: Background Although immune checkpoint inhibitors (ICIs) combined… https://t.co/8

14 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.